Palvella Therapeutics (PVLA) Enterprise Value (2015 - 2026)

Palvella Therapeutics (PVLA) has reported Enterprise Value for 14 consecutive years, with -$261.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 246.25% year-over-year to -$261.9 million; the TTM figure through Mar 2026 stood at -$261.9 million (down 246.25% YoY), while the FY2025 annual figure was -$58.0 million, up 30.65% from the prior year.
• Enterprise Value fell to -$261.9 million in Q1 2026 per PVLA's latest filing, from -$58.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$6.2 million in Q1 2024 and bottomed at -$261.9 million in Q1 2026.
• Historically, Enterprise Value has averaged -$69.1 million across 5 years, with a median of -$63.6 million in 2025.
• Annual changes were most pronounced in 2024 — Enterprise Value jumped 89.05% — and 2025, when it tumbled 1110.4%.
• Palvella Therapeutics' Enterprise Value stood at -$59.2 million in 2022, then soared by 72.42% to -$16.3 million in 2023, then sank by 412.27% to -$83.6 million in 2024, then soared by 30.65% to -$58.0 million in 2025, then plunged by 351.61% to -$261.9 million in 2026.
• Business Quant data shows PVLA's Enterprise Value at -$261.9 million in Q1 2026, -$58.0 million in Q4 2025, and -$63.6 million in Q3 2025.